CJC 1295 With DAC For Sale 2mg

CJC 1295 with DAC

CJC 1295 with DAC (also known as DAC:GRF or CJC-1295 DAC) is a long-acting synthetic analog of Growth Hormone-Releasing Hormone (GHRH). This 29-amino-acid peptide features a Drug Affinity Complex (DAC) modification that binds to albumin in the bloodstream, dramatically extending its half-life to approximately 6–8 days (based on human studies), enabling sustained elevation of endogenous growth hormone (GH) and IGF-1 levels.

Key Benefits and Potential Uses

CJC 1295 with DAC is primarily investigated in research for prolonged GH stimulation:

• Supporting increased lean muscle mass, protein synthesis, and strength gains.
• Promoting fat loss, particularly visceral and stubborn adipose tissue reduction.
• Enhancing recovery from exercise, training, or injury with improved tissue repair and reduced inflammation.
• Improving sleep quality, energy levels, skin elasticity, and overall vitality.
• Contributing to better body composition, bone density, and potential anti-aging effects through sustained IGF-1 elevation.
• Often used in protocols aiming for consistent, elevated GH/IGF-1 levels over days rather than short pulses.

It functions by:

• Mimicking endogenous GHRH to stimulate pituitary GH secretion in a sustained, dose-dependent manner.
• Producing prolonged increases in plasma GH (2- to 10-fold for 6+ days) and IGF-1 (0.5- to 3-fold for 9–11 days or longer with multiple doses).
• Providing a more continuous GH profile compared to shorter-acting GHRH analogs.

This extended action makes it convenient for less frequent dosing while maintaining elevated anabolic signaling.

Administration Options For

Typically supplied as lyophilized powder in vials (e.g., 2mg, 5mg, or 10mg) for reconstitution with bacteriostatic water. Administered via subcutaneous injection. In research settings, dosing often ranges from 1–2 mg per week (or 30–60 mcg/kg body weight), split into 1–2 injections weekly due to the long half-life. Protocols may involve cycling or steady use.

CJC 1295 with DAC

Synonyms / Designations: CJC 1295 DAC, DAC:GRF
CAS Number: 863288-34-0
Molecular Formula: C152H252N44O42
Molecular Weight: 3367.9 g/mol
Peptide Classification: Synthetic growth hormone–releasing hormone (GHRH 1–29) analogue conjugated with Drug Affinity Complex (DAC)
Purity: ≥ 99 % (HPLC, typical)
Appearance: White to off-white lyophilised powder
Pack Size: 2 mg (total)
Storage: Desiccated, protected from light, stored at –20 °C
Solubility: Soluble in sterile water and buffered aqueous solutions

Description & Mechanism

CJC 1295 with DAC is a synthetic analogue of growth hormone–releasing hormone (GHRH 1–29) that has been chemically modified through conjugation with a Drug Affinity Complex (DAC). The DAC moiety consists of a reactive linker designed to form a covalent association with circulating serum albumin, resulting in prolonged systemic persistence of the peptide in experimental systems. This bioconjugation alters pharmacokinetic behaviour while preserving the core peptide sequence responsible for receptor interaction.

In biochemical and cellular research models, CJC 1295 with DAC interacts with the GHRH receptor expressed on pituitary-derived cells, initiating intracellular signalling cascades associated with growth hormone secretion. Preclinical and clinical research studies have examined receptor activation dynamics, signalling duration, and downstream endocrine pathway engagement under extended exposure conditions. Observed molecular and physiological responses are dependent on experimental design, dosing paradigm, and model system, and are used to investigate prolonged GHRH receptor signalling rather than defined biological or physiological outcomes.

Applications in Research

• As a molecular probe to study GHRH receptor binding and activation dynamics.
• Investigation of growth hormone axis signalling and endocrine feedback mechanisms.
• In cellular assays examining downstream transcriptional and signalling responses.
• In preclinical or clinical research models assessing extended-duration peptide–receptor interaction resulting from albumin binding

Handling, Reconstitution & Stability

• Weigh under dry conditions; peptide is hygroscopic.
• Reconstitute in sterile water or appropriate buffered aqueous solution depending on assay requirements.
• Avoid vigorous agitation during dissolution due to peptide–DAC conjugation.
• Filter sterilize if required (e.g. 0.22 µm) immediately prior to use.
• Aliquot and store reconstituted solutions at –20 °C (or lower) to avoid repeated freeze–thaw cycles.
• Inspect solutions for precipitation or changes in clarity before use in sensitive assays.